Online citations, reference lists, and bibliographies.
← Back to Search

Mesothelioma In Australia: A Review

Arthur (Bill) W Musk, N. Klerk, Fraser J Brims
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The incidence of malignant mesothelioma in Australia is among the highest in the world as a result of widespread use of asbestos by industry and in construction throughout the 20th century. The risk of developing malignant mesothelioma after asbestos exposure is dose-related; a transient, low dose exposure confers a correspondingly very low risk of disease. Malignant mesothelioma is a heterogeneous disease, partly explaining the limited role of biomarkers in screening and diagnosis. The prognosis remains poor, and early advice on medico-legal compensation and a collaborative team approach to managing malignant mesothelioma are both essential. Chemotherapy can have a modest treatment effect in some people. New therapies, such as immunotherapy, do not yet have a defined role in the treatment of malignant mesothelioma. As treatment options for malignant mesothelioma are limited and no cure is available, there is no established role for early detection or screening of at risk populations. A multidisciplinary approach to caring for patients with malignant mesothelioma and their carers is vital.
This paper references
10.1097/MCP.0b013e3282fcea50
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues
H. E. Davies (2008)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1038/bjc.2012.23
Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up
G. Berry (2012)
10.1136/oemed-2016-103721
Asbestos exposure and histological subtype of malignant mesothelioma
P. Franklin (2016)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1183/09031936.00000811
Predicting survival in malignant mesothelioma
A. Musk (2011)
10.1001/jama.2012.5535
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
10.1038/bjc.2017.20
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
Sanjeevan Muruganandan (2017)
Monash Centre for Occupational and Environmental Health
Australian Mesothelioma Registry (2016)
10.1164/rccm.201409-1687LE
Ultra-low-dose chest computer tomography screening of an asbestos-exposed population in Western Australia.
F. Brims (2015)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1186/1745-6215-15-367
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
Samal Gunatilake (2014)
10.1111/j.1445-2197.2009.05060.x
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy *
J. Alvarez (2009)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
A phase II study of nivolumab in malignant pleural mesothelioma ( NivoMes ) : with translational research ( TR ) biopsies
J Quispel-Janssen (2017)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1002/(SICI)1097-0215(19980130)75:3<355::AID-IJC5>3.0.CO;2-1
Vitamin A and cancer prevention I: Observations in workers previously exposed to asbestos at Wittenoom, Western Australia
A. Musk (1998)
10.1007/s13665-013-0045-1
Prognostic factors for malignant pleural mesothelioma
F. Brims (2013)
10.1093/ANNHYG/44.8.565
The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.
J. Hodgson (2000)
10.1093/OCCMED/33.4.190
The epidemiology of mesothelioma.
K. Browne (1983)
The Third Wave of Asbestos Disease: Exposure to Asbestos in Place--Public Health Control. Conference. New York, New York, June 7-9, 1990.
R. Dodson (1991)
10.1002/ijc.27758
Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia
N. de Klerk (2013)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.5694/mja11.10125
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen (2011)
10.1016/j.jtho.2015.12.108
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
F. Brims (2016)
Ef fi cacy and safety of an intensi fi ed schedule of tremelimumab for chemotherapy - resistant malignant mesothelioma : an open - label , single - arm , phase 2 study
L Calabro (2015)
10.1136/oem.2004.018531
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis
A. Reid (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar